Skip to main content

Table 1 Baseline Patient Characteristics

From: Patterns, predictors and subsequent outcomes of disease progression in metastatic renal cell carcinoma patients treated with nivolumab

Characteristics No (%)n = 90
Mean age, years (SD) 65 (9.88)
Male Gender 67 (74)
ECOG PS
 0 34 (41)
 1 33 (40)
  > 2 15 (18)
IMDC Risk Group
 Favorable 12 (14)
 Intermediate 61 (69)
 Poor 15 (17)
 Prior Nephrectomy 67 (97)
 No of prior systemic therapies, median, No. (range) 2 (1, 6)
No of prior systemic therapies
 1 42 (47)
 2 24 (27)
 3 16 (18)
 4 6 (7)
  > 5 2 (2)
Most common prior systemic therapies
 Sunitinib 64 (71)
 Pazopanib 30 (33)
 Axitinib 35 (39)
Sites of metastases at baseline
 Brain 14 (16)
 Bones 37 (41)
 Lungs 65 (72)
 Liver 27 (30)
 Lymph Nodes 58 (64)
 Pleural 18 (20)
 Adrenal 20 (22)